1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Eastgate Biotech Corp.

Eastgate Biotech Corp.

ETBI
Eastgate Biotech Corp.US flagOther OTC
0.00
USD
+0.00
- -
5.56MMarket Cap
Eastgate Biotech Corp.
ETBI
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.02
- -
- -
-0.03
-0.05
-0.1
-0.02
-0.01
-0.01
Basic EPS, GAAP
- -
- -
- -
- -
-0.01
-0.03
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
-0.01
-0.05
-0.02
-0.01
-0.01
- -
Book Value per Share
- -
- -
- -
-0.01
-0.05
-0.02
-0.01
-0.01
- -
Tangible Book Value per Share
2
12
12
24
32
50
192
305
668
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-3,159.54
- -
-8,649.62
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
-2
-5
-4
-3
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-3,242.8
- -
-9,598.82
Profit Margin (%)
- -
- -
- -
-1
-2
-2
-3
-5
-7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
-1
-2
-1
-2
-5
-5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'17
Jun'17
Sep'17
ST Debt
2
2
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
323
1,137
1,137
Market Capitalization
14
2
1

Working Capital

FRC

•

in mil. unless spec.
Mar'17
Jun'17
Sep'17
Total Current Assets
- -
1
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
6
7
Payables & Accruals
3
3
4
ST Debt
2
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
197.72%
86.13%
Free Cash Flow
- -
- -
-31.48%
Net Income, GAAP
- -
459.98%
-30.45%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
-0.02
-0.01
- -
- -
-0.02
2016
- -
- -
- -
- -
-0.01
2017
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
Similar Companies
Interpharm Holdings, Inc. (IPAH)
Zenotech Laboratories Limited (ZENOTECH.BO)
Tsuruha Holdings Inc. (3391.T)
Damora Therapeutics, Inc. (GLTO)
Shukra Pharmaceuticals Limited (SHUKRAPHAR.BO)
Nanologica AB (publ) (NICA.ST)
Business
Eastgate Biotech Corp. (Ticker: ETBI) develops and commercializes novel therapeutics and diagnostics targeting chronic diseases and infectious conditions, with a focus on cannabinoid-based formulations and biotechnology platforms for drug delivery. The company offers a portfolio of pharmaceutical products including proprietary oral and topical cannabinoid formulations for pain management, inflammation, and neurological disorders; diagnostic testing kits for infectious diseases such as COVID-19 and respiratory pathogens; and regenerative medicine solutions leveraging stem cell technologies and biologics. These products are distributed through partnerships with healthcare providers, pharmacies, and research institutions primarily in North America, with expanding operations in Europe and Asia. Founded in 2012 and headquartered in Vancouver, British Columbia, Canada, Eastgate Biotech operates in the biotechnology and healthcare segments, serving pharmaceutical companies, clinical laboratories, and direct-to-consumer markets. In the past year, the company announced a strategic partnership with a leading Canadian research institute for advanced cannabinoid delivery systems; completed a $5 million private placement funding round to support Phase II clinical trials; and launched a new line of at-home diagnostic tests for viral detection, marking its entry into consumer health products. No subsidiaries or parent company relationships are reported.

Company News

Company News APIChatGPT

  • defenseworld.net

    Eastgate Biotech (OTCMKTS:ETBI) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?